Estimating the best PCSK9 vaccine design for atherosclerosis based on mouse models: A frequentist network meta-analysis
Global Cardiology Science and Practice · 21.05.2025 · 2025 (2)
DOI: 10.21542/gcsp.2025.19 ↗Kurz gefasst
Netzwerk-Metaanalyse in der Zeitschrift Global Cardiology Science and Practice, online erschienen am 21.05.2025. Verfasst von Muhammad Iqhrammullah und 9 weiteren Autor:innen. Beteiligte Einrichtung: Postgraduate School of Public Health, Universitas Muhammadiyah Aceh, Banda Aceh, Indonesia. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Proprotein convertase subtilisin/kexin 9 (PCSK9) plays a crucial role in regulating the plasma levels of low-density lipoprotein cholesterol (LDL-C) and low-density lipoprotein receptor (LDLR). In contrast, vaccines have been developed to induce PCSK9-specific antibodies, which could improve dyslipidemia in atherosclerotic animal models. The aim of this study was to determine the best PCSK9 vaccine design for improving dyslipidemia and atherosclerosis in animal studies.
Methods
A systematic search was performed on PubMed, Scopus, and Web of Science for studies published as of August 2024. Studies that developed a PCSK9 vaccine and reported its efficacy in mouse models were included. A random-effects model was used to conduct a frequentist network meta-analysis. The standardized mean difference (SMD) and 95% confidence interval (CI) were used as size effects. Heterogeneity in the model was judged based on the I2 values.
Results
Six studies, published between 2014 and 2024, were included. There were 8 vaccine designs developed using different peptides, carriers, and delivery systems. Vaccines prepared with human PCSK9-003 epitope peptide (F-A-Q-S-I-P-W-N) with Qb virus-like particles consistently appeared to be the best vaccine design for the reduction of total cholesterol (p
Autor:innen und Institutionen
- Postgraduate School of Public Health, Universitas Muhammadiyah Aceh, Banda Aceh, Indonesia.
- School of Medicine, Universitas Syiah Kuala, Banda Aceh, Indonesia.
- Faculty of Medicine, Universitas Sam Ratulangi, Manado, Indonesia.
- Department of Cardiology and Vascular Medicine, Dr. Zainoel Abidin Hospital, Banda Aceh, Indonesia.
- Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.
- Department of Cardiology and Vascular Medicine, Dr. Soetomo Hospital, Faculty of Medicine, University of Airlangga, Surabaya, Indonesia.
Zitieren
APA
Iqhrammullah, M., Muzaffar, A., Rampengan, D. D. C. H., Ichwan, C., Kalaij, A. G. I., Al-Gunaid, S. T., Purba, N. A., Gusti, N., Sufri, M. R., & Purnawarman, A. (2025). Estimating the best PCSK9 vaccine design for atherosclerosis based on mouse models: A frequentist network meta-analysis. Global Cardiology Science and Practice, 2025(2). https://doi.org/10.21542/gcsp.2025.19
Vancouver
Iqhrammullah M, Muzaffar A, Rampengan DDCH, Ichwan C, Kalaij AGI, Al-Gunaid ST, et al. Estimating the best PCSK9 vaccine design for atherosclerosis based on mouse models: A frequentist network meta-analysis. Global Cardiology Science and Practice. 2025;2025(2). doi:10.21542/gcsp.2025.19
BibTeX
@article{Iqhrammullah2025,
author = {Iqhrammullah, Muhammad and Muzaffar, Asyraf and Rampengan, Derren David Christian Homenta and Ichwan, Chairul and Kalaij, Ayers Gilberth Ivano and Al-Gunaid, Seba Talat and Purba, Nur Adiba and Gusti, Naufal and Sufri, Muhammad Rinaldi and Purnawarman, Adi},
title = {Estimating the best PCSK9 vaccine design for atherosclerosis based on mouse models: A frequentist network meta-analysis},
journal = {Global Cardiology Science and Practice},
year = {2025},
volume = {2025},
number = {2},
doi = {10.21542/gcsp.2025.19}
}
EUVIMED